To include your compound in the COVID-19 Resource Center, submit it here.

Lixisenatide/insulin glargine regulatory update

FDA’s Endocrinologic and Metabolic Drugs Advisory Committee voted 12-2 to recommend approval of iGlarLixi lixisenatide/insulin glargine from

Read the full 174 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE